tbuckley/cabot-search huggingface dataset:
Gemella Morbillorum Associated Mediastinitis following EUS-FNA of a Posterior Mediastinal Lymph Node
Authors: T Savides, V Singh
Journal: Endoscopy (2006)

Background: Only a few reports of mediastinitis after EUS-FNA of mediastinal reports have been reported in the literature. We present the first reported case of Gemella morbillorum mediastinitis following EUS-FNA of a posterior mediastinal lymph node (LN). Methods: Case report using retrospective review of medical records. Results: A 78-year-old man with a history of a T3N0M0 adenocarcinoma of the colon removed four years earlier underwent routine surveillance PET scan and was found to have intense activity corresponding to a 1cm diameter aorto-pulmonary window LN which was suspicious for malignancy. The patient had a history of non-insulin dependent diabetes and hypertension. Trans-esophageal EUS-FNA (5 passes, 22G needle) of the LN revealed benign lymphoid tissue. No antibiotic prophylaxis was given. 5 days later, he presented with retrosternal chest pain, fever, chills and leukocytosis. A chest CT scan demonstrated inflammatory changes consistent with mediastinitis adjacent to the enlarged lymph node which had undergone EUS-FNA. Blood cultures grew Gamella morbillorum which was sensitive to penicillin and ceftriaxone. The patient was treated with ceftriaxone and metronidazole. Clinical symptoms resolved, and blood cultures were negative. A follow-up CT scan, 2 weeks post-discharge, revealed persistent posterior mediastinal inflammation with spondylitis and diskitis at the T6-T7 level. Conclusions: 1) Mediastinitis can occur after trans-esophageal EUS/FNA of posterior mediastinal lymph nodes. 2) Gemella morbillorum should be considered in the list of bacteria that may be associated with infective complications following EUS-FNA. 3) Endosonographers should keep a high index of suspicion for infection following EUS/FNA of mediastinal lymph nodes, and not only cystic lesions. 4) Prophylactic antibiotics may be considered in selected patients undergoing trans-esophageal EUS/FNA.
SHORTER DOOR-TO-BALLOON TIME IS ACCOMPANIED BY REDUCED HEART FAILURE AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION DESPITE A TEMPORAL INCREASE IN HEART FAILURE BEFORE PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Authors: Li-Ling Tan, Huili Zheng, Khuan Chow, Joshua Loh, Terrance Chua, Huay-Cheem Tan, David Foo, Hean Yee Ong, Khim-Leng Tong, Mark Richards, Mark Chan
Journal: Journal of the American College of Cardiology (2016)
Chilaiditi's Syndrome
Authors: BELUR CHANDRAMOULY, RAKESH SHAH, PETER NARDI
Journal: Clinical Nuclear Medicine (1997)

Chilaiditi's Syndrome is a condition in which the digestive tract interposes between the diaphragm and the liver. A routine Ga-67 scintigraphy in the evaluation of a patient with AIDS who had a fever and lymphadenopathy showed linear increased activity along the superior margin of the liver, which was caused by interposition of colon as seen on the chest radiography.
FGFR1 and FGF Coamplification in Breast Cancer.
Authors: L. Albiges, L. Albiges, V. Quidville, A. Valent, M. Mathieu, F. Drusch, B. Job, S. Koscielny, S. Delaloge, F. Andre, F. Andre
Journal: Cancer Research (2009)

Abstract Background:FGFR1 is a tyrosine kinase receptor involved in cell proliferation, migration and differentiation. FGFR1 gene is amplified in about 10% of breast cancer. Several studies have previously reported that FGFR1 inhibition could lead to a decrease in cell proliferation. Recent data obtained in prostate cancer have shown that FGFR1 activation could mediate epithelial to mesenchymal transition. In the present study, we evaluated the rational to target FGFR1 in clinical setting.Material and methods:We first assessed whether FGFR1 amplification was associated with a specific breast cancer phenotype. We assessed FGFR1 amplification by CGH array on 235 samples and by FISH (Z-2072, Spec FGFR1/Cen8 dual color probe, Zytovision®) on 260 samples, not included in the CGH part. We then assessed the functional effects of FGFR1 inhibitions in vitro. The antiproliferative effect of E3810 (FGFR1 inhibitor) was assessed both on FGFR1-non amplified (T47D/MCF7) and FGFR1 amplified (SUM44PE/MDA134) cell lines. Effect of FGFR1 inhibition was assessed on gene expression profiling.Results:When assessed by FISH, FGFR1 amplification was observed in 23/260 cases. Most of the samples (62%) exhibited an ER+/PR- phenotype, suggesting activation of intracellular kinase. FGFR1 amplification was observed in 24 out of 235 samples (10%). Interestingly, FGFR1 amplification was associated with gene gain in FGF3/FGF4/FGF19 (11q13) (55% versus 22%, p=0.05). FGFR1 inhibition by E-3810 inhibits MAPk phosphorylation, cell proliferation. A differential IC 50 for cell proliferation was observed between amplified cell lines and control cell lines. Preliminary data on gene expression profiling suggest that FGFR1 inhibition on breast cancer cells could lead to significant decrease in the Sox9 expression, a protein involved in epithelial to mesenchymal transition.Conclusion:FGFR1-amplified breast cancers present a discrete phenotype, including a high rate of ER+/PR- and high rate of FGF3/4/19 gains. Pharmacologic inhibition of FGFR1 leads to cell proliferation decrease and modulation of genes involved in EMT. These data suggest that there is a rational to target FGFR1 in clinical setting in patients with FGFR1-amplified breast cancer. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4170.
RENAL RESISTIVE INDEX IS RELATED TO CARDIAC AND AORTIC HAEMODYNAMICS IN THE EARLY STAGES OF ESSENTIAL HYPERTENSION
Authors: Konstantinos P. Tsioufis, Konstantinos Kintis, Kyriakos Dimitriadis, Evaggelia Koutra, Ioannis Liatakis, E. Andrikou, Alexandros Kasiakogias, Ioannis Andrikou, C. Thomopoulos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2015)
Abstract 906: Therapeutic potential of JAK/STAT signal inhibition in prostate cancer by the JAK inhibitor AZD1480.
Authors: Marco A. De Velasco, Yurie Kura, Naomi Ando, Emiko Fukushima, Yuji Hatanaka, Yutaka Yamamoto, Nobutaka Shimizu, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura
Journal: Cancer Research (2013)

Abstract Signal transducers and activators of transcription (STAT) were originally identified as components of cytokine signal transduction pathways but are now also recognized as key regulators of apoptosis, proliferation, angiogenesis and immune responses in many malignant diseases. Activation of STAT3 occurs by the binding of various cytokines to its receptors leading to the activation of the JAK/ STAT3 signaling pathway. Of these cytokines, interleukin-6 (IL-6) has been implicated in regulating growth of various malignant tumors. Activated IL-6 has also been shown to be elevated in the sera from patients with metastatic prostate cancer, and persistent activation of STAT3 is a common feature. To better characterize the potential role of JAK/STAT3 as a therapeutic target for advanced prostate cancer, we used the JAK1/2 inhibitor, AZD1480 to suppress the transcriptional activation of STAT3 in a PTEN-conditional knockout mouse model of prostate cancer. Prostate tumors from homozygous PTEN-mutant mice share many characteristics of human prostate cancer, including increased activation of the JAK/STAT3 signaling cascade. Our pharmacodynamic studies show that AZD1480 elicited a strong inhibition of STAT3 signal activation leading to decreased tumor cell proliferation, and induction of apoptosis. Our drug intervention studies show that persistent suppression of STAT3 signaling results in a reduction of tumor growth characterized by a decrease in tumor cell proliferation, induction of apoptosis, and decreased angiogenesis. However, PI3K/Akt and MAPK signaling were upregulated in response to STAT3 signal inhibition. Our findings show a strong antitumor effect for STAT3 signal inhibition and may be a promising therapeutic option for prostate cancer; however, it still requires further optimization in order to maximize its clinical potential. Citation Format: Marco A. De Velasco, Yurie Kura, Naomi Ando, Emiko Fukushima, Yuji Hatanaka, Yutaka Yamamoto, Nobutaka Shimizu, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura. Therapeutic potential of JAK/STAT signal inhibition in prostate cancer by the JAK inhibitor AZD1480. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 906. doi:10.1158/1538-7445.AM2013-906
AB0716 Disease Severity as Measured by PROMS or Need for Second Line Treatment in Inflammatory Bowel Disease Associated Arthropathy: Comparison to Other Spondyloarthritis Subgroups
Authors: P. Drivelegka, N. Papachrysos, I.F. Petersson, A. Bremander, L.T. Jacobsson
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Inflammatory Bowel Disease associated arthropathy (IBD-aA) can cause impaired function but the level of activity limitations in comparison with other subgroups of spondyloarthritis (SpA) is unknown. Furthermore, data on the association of IBD-aA with the severity of bowel disease is limited. <h3>Objectives</h3> To compare disease severity as measured by patient reported outcome (PROMs): 1) in patients with IBD-aA with peripheral and axial musculoskeletal manifestations to those in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) respectively, 2) by severity of IBD-aA reflected by whether second line treatment had be given. <h3>Methods</h3> The SpA Scania cohort consists of all the subjects aged 15 years or older in the Skåne region (1.2 million inhabitants in southern Sweden) having recieved a diagnosis of any type of Spondyloarthritis during 2003-2007 at primary or specialised care visits (N=5771) recorded in the Skåne Health Care Register (SHCR). This included patients with Ankylosing Spondylitis (26%), Undiffentiated Spondyloarthritis (22%), Psoriatic Arthritis (39%) and IBD-aA (2.3%). A postal questionnaire was sent in 2009 to all the subjects aged 15 years or older including questions on PROMs with an overall response rate of 58%. Of the 65 patients with IBD-aA responding to the questionnaire a structured review of medical records verified both IBD and arthritis in 80% (N=52), from whom questionnaire data was used in the present analyses. The occurrence of axial or peripheral musculoskeletal disease and given second line therapy (surgery or treatment with TNF-inhibitor for IBD) were retrieved through the medical record review. <h3>Results</h3> Fifty-two patients records were analysed (17 men, mean age 39.8). Patients with axial IBD-aA (N=23) had comparable values for BASDAI (4.8 vs 4.0, p=0.19) and BASFI (4.1 vs 3.4, p=0.44) to AS patients (N=711). Patients with peripheral IBD-aA (N=44) had comparable values for global health (numeric rating scale) (4.5 vs 4.1, p=0.51) compared to PsA patients (N=1225). Severe bowel disease, defined as the need of anti-TNFa therapy or surgery, was observed in 52% (n=27) of the patients with IBD-aA. Perceived health according to PROMs was similar in the patients with and without severe IBD (BASDAI: 5.1 vs 4.9 p=0.71, BASFI: 4.5 vs 3.3 p=0.13, global health: 4.8 vs 4.2 p=0.29). <h3>Conclusions</h3> Patients with IBD-aA tend to have worse perceived health compared to patients with AS and PsA. This warrants further and larger studies of this subgroup of SpA. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4558
P967 CAN THE MODEL FOR END-STAGE LIVER DISEASE SCORE REPLACE THE INDOCYANINE GREEN CLEARANCE TEST IN THE SELECTION OF RIGHT HEMIHEPATECTOMY IN CHILD–PUGH CLASS A?
Authors: S.R. Han, J. Lee, J.Y. Choi, W. Cho, S. Lee, S.-S. Yang, J.M. Kim, C.H.D. Kwon, J.-W. Joh
Journal: Journal of Hepatology (2014)
GPs are urged to take on greater role in safeguarding children
Authors: J. Wise
Journal: BMJ (2014)

GPs are ideally placed to take on a greater role in safeguarding children by spotting early warning signs of maltreatment and using their skills to provide children and their families with direct support, a new report concludes.1

The report estimates that for every child who is subject to a child protection plan there are another eight who are experiencing neglect and emotional abuse but are not receiving services. The report, a collaboration between the Royal College of General Practitioners, the National Society for the Prevention of Cruelty to Children (NSPCC), and researchers from the University of Surrey and University College London’s Institute of Child …
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
Authors: Niels Halama, Inka Zoernig, Anna Berthel, Christoph Kahlert, Fee Klupp, Meggy Suarez-Carmona, Thomas Suetterlin, Karsten Brand, Juergen Krauss, Felix Lasitschka, Tina Lerchl, Claudia Luckner-Minden, Alexis Ulrich, Moritz Koch, Juergen Weitz, Martin Schneider, Markus W. Buechler, Laurence Zitvogel, Thomas Herrmann, Axel Benner, Christina Kunz, Stephan Luecke, Christoph Springfeld, Niels Grabe, Christine S. Falk, Dirk Jaeger
Journal: Cancer Cell (2016)
Abstract 3879: High-throughput, homogeneous <i>in cyto</i> assays to monitor histone H3 post-translational modifications
Authors: Lucille Beaudet, Jean-Philippe Lévesque Sergerie, Marie Boulé, Anne Labonté, Jean-François Michaud, Nathalie Rouleau, Mathieu Arcand
Journal: Cancer Research (2012)

Abstract Histone proteins are an integral part of DNA packaging into chromatin, a dynamic process partly regulated by post-translation modification of histone N-terminal tails. Aberrant histone acetylation (ac) or methylation (me) levels is associated with a number of diseases. For example, histone deacetylases (HDACs and sirtuins) regulate the expression of many genes involved in neurodegeneration and can be aberrantly expressed in different tumors. In addition, deregulation of the methyl marks H3K4me3 and H3K27me3 are found associated with the development of several types of cancer. This work presents the development of high-throughput AlphaLISA® in cyto assays to monitor four specific histone marks: H3K9ac, H3K4me2, H3K27ac and H3K27me3. These assays were performed using an all-in-one well histone extraction protocol requiring no acid extraction or centrifugation steps. The level of each histone mark was first measured in cell titration experiments, seeding cells from 500 to 10 000 in 384 well plates. The chemical modulation of H3K4me2, H3K9ac and H3K27ac was monitored following overnight treatment of HeLa, HEK293, and Jurkat cells with the non-selective histone deacetylase inhibitors sodium butyrate and trichostatin A. Signal increases were all corroborated by Western blot analysis using the same antibodies as in the AlphaLISA detection assay. In the absence of chemical modulation, measurement of different H3K27me3 mark levels was performed in two B cell lymphoma cell lines: OCI-LY-19 and SU-DHL-6. OCI-LY-19 cells express wild-type EZH2 methyltransferase while SU-DHL-6 cells bear a heterozygous EZH2 mutation (Y641N) that alters its substrate selectivity, resulting in increased H3K27me3 levels. These novel cell-based assays showed suitability for high-throughput screening (HTS) protocols as demonstrated by Z’ factors superior to 0.6 for all four marks. In summary, these homogeneous cell-based AlphaLISA assays allow the simple and rapid monitoring of cellular histone H3 mark levels. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3879. doi:1538-7445.AM2012-3879
P761 THE IMPACT OF FIBROSIS ON THE RISK OF LONG-TERM MORBIDITY AND MORTALITY IN CHRONIC HEPATITIS C PATIENTS TREATED IN THE VETERANS ADMINISTRATION HEALTH CARE SYSTEM
Authors: J.S. McCombs, T. Matsuda, I. Tonnu-Mihara, S. Sasb, P. Hines, G. L'Italien, A. Kalsekar, Y. Yuan
Journal: Journal of Hepatology (2014)
Abstract 1957: PMEPA1 promotes androgen receptor negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21Cip1 signaling pathway
Authors: Rong Liu, Zhongmei Zhou, Jian Huang, Ceshi Chen
Journal: Cancer Research (2011)

Abstract The PMEPA1 gene has been shown to suppress the androgen receptor (AR) and TGFβ signaling pathways and is abnormally expressed in prostate tumors. However, the role and mechanism action of PMEPA1 in AR-negative prostate cancer are unclear. Here, we demonstrate that inhibition of PMEPA1 suppresses AR-negative RWPE1 and PC-3 prostate cell proliferation through upregulating the p21 transcription. Additionally, PMEPA1 overexpression suppresses the p21 expression and promotes cell proliferation. PMEPA1 is induced by TGFβ as a negative feedback loop to suppress Smad3 phosphorylation and nuclear translocation, upregulates c-Myc, downregulates p21, and promotes PC-3 cell proliferation. The PMEPA1 functions depend on its Smad2/3 binding motif. Consistently, depletion of Smad3/4, but not Smad2, blocks the PMEPA1's functions of regulating c-Myc and p21. Importantly, stable depletion of PMEPA1 in PC-3 inhibits xenograft growth. Finally, we found that PMEPA1 is overexpressed in a subset of prostate cancer cell lines and tumors. These findings suggest that PMEPA1 may promote AR-negative prostate cancer cell proliferation through p21. (This work was supported by a grant from the Department of Defense (W81XWH-07-1-0191) and a grant from the American Cancer Society (RSG-08-199-01). Dr. Liu is supported by a postdoctoral fellowship from American Urological Association Foundation.) 1 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1957. doi:10.1158/1538-7445.AM2011-1957
Selective inhibition of VEGFR2 activity with a human anti-VEGF monoclonal antibody decreases tumor growth and macrophage infiltration in an orthotopic model of breast cancer.
Authors: SP Dineen, KD Lynn, CL Roland, LA Payton, RA Brekken
Journal: Cancer Research (2009)

Abstract Abstract #1034 In general tumor associated macrophages confer a negative prognosis in patients with breast cancer. This is due in part to the fact that macrophages can promote angiogenesis and mediate the angiogenic switch in tumors. Vascular endothelial growth factor (VEGF) is a primary stimulant of angiogenesis as well as a macrophage chemotactic protein. Inhibition of VEGF is an attractive therapeutic strategy that has shown to be beneficial in combination with chemotherapy for some breast cancer patients. However, the mechanism by which inhibition of VEGF affects tumor growth appears to involve more than its effect on endothelial cells. We have previously shown that 2C3 (PGN-310), a mouse monoclonal antibody that prevents VEGF from binding to VEGF receptor 2, decreases tumor growth, angiogenesis, and macrophage infiltration into pancreatic tumors. In this study, we test a fully human version of 2C3, termed r84 (PGN-311), for its effect on established orthotopic MDA-MB-231 breast tumors in SCID mice. Orthotopic tumors were established by injecting one million MDA-MB-231 cells into the mammary fat pad of SCID mice. Therapy with saline (n=5), bevacizumab (n=8), 2C3 (n=5), or r84 (n=9) at 250 μg/ip injection twice weekly was initiated on day 26 post tumor cell injection (mean initial tumor volume = 150 mm3) and continued for approximately 3 weeks. Upon sacrifice, tumor weight was determined and the tumor and other organs were snap frozen or fixed in formalin and paraffin-embedded for histology. Anti-VEGF therapy inhibited growth of orthotopic breast tumors (on day 48, Mean ± SEM: control, 822 ± 160; bevacizumab, 344 ± 29; 2C3, 309 ± 69; r84, 368 ± 38 mm3;all p &amp;lt; 0.001 vs control). Furthermore, immunohistochemical analysis of tumors from control and anti-VEGF treated animals demonstrated that each anti-VEGF therapy reduced microvessel density and macrophage infiltration. Additionally, we also determined that inhibition of VEGF activity with 2C3 reduces VEGF-induced migration of MDA-MB-231 cells in vitro in a transwell assay. In summary, we demonstrate that r84 a unique fully human anti-VEGF antibody is effective in reducing tumor microvessel density, macrophage infiltration into tumors, and the growth of breast tumors implanted into SCID mice. These data suggest that inhibition of VEGF receptor 2 activity with an anti-VEGF monoclonal antibody is sufficient for effective blockade of the pro-tumorigenic activities of VEGF. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1034.
INSUFFICIENT LEAFLET REMODELING CAUSES MITRAL REGURGITATION IN PATIENTS WITH ATRIAL FIBRILLATION
Authors: Nobuyuki Kagiyama, Akihiro Hayashida, Misako Toki, Takao Morikawa, Tomonori Miki, Yasuhiko Kamata, Minako Ohara, Atsushi Hirohata, Keizo Yamamoto, Kiyoshi Yoshida
Journal: Journal of the American College of Cardiology (2016)
Caucus Informs Congress About Biomedical Research
Authors: E. Blume
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Caucus Informs Congress About Biomedical Research Get access Elaine Blume Elaine Blume Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 24, December 1993, Pages 1989–1990, https://doi.org/10.1093/jnci/85.24.1989 Published: 01 December 1993
Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia
Authors: Steven G. Deeks, Terri Wrin, Teri Liegler, Rebecca Hoh, Matthew Hayden, Jason D. Barbour, Nicholas S. Hellmann, Christos J. Petropoulos, Joseph M. McCune, Marc K. Hellerstein, Robert M. Grant
Journal: New England Journal of Medicine (2001)

In many patients with human immunodeficiency virus (HIV) infection, therapy with potent antiretroviral drugs does not result in complete suppression of HIV replication. The effect of cessation of therapy in these patients is unknown.
TEMPORAL TRENDS IN ADMISSION STATUS AND PREDICTED MORTALITY AMONG PATIENTS UNDERGOING NON-ACUTE PERCUTANEOUS CORONARY INTERVENTION: A REPORT FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY
Authors: Amit Vora, Dadi (David) Dai, Hitinder Gurm, Amit Amin, John Messenger, Ehtisham Mahmud, Laura Mauri, Tracy Wang, Matthew Roe, Jeptha Curtis, Eric Peterson, Sunil Rao
Journal: Journal of the American College of Cardiology (2015)